The Asia Pacific size over the counter drugs market was estimated at USD 51.57 Million in 2020. It is further projected to reach USD 83.09 Million by 2024 at a CAGR of 10.01% during the forecast period from 2019 to 2024.
Steadily increasing population in the region, particularly in countries like China, India, and Bangladesh, leading to high penetration of the market and is boosting the growth of the over the counter (OTC) drugs market in the Asia Pacific. Advancements in distribution channels led to increased accessibility of OTC drugs in the region, which is another major factor fuelling up the growth of the over-the-counter drugs market in the Asia Pacific. The presence of key market players in this region is another major factor supporting the growth rate of the over-the-counter drugs market in this area.
Using traditional home remedies in countries like India and others, owing to available knowledge on the internet, is limiting the growth of the Asia Pacific over the counter drugs market. Lack of awareness regarding effective drugs in rural areas is also restraining the growth of the local market.
The rise in account of research and development activities from the private and public organizations for developing drug delivery systems, effective drugs that can be accessible at the nearest drug stores, medical shops, and online shopping is likely to expand growth opportunities over-the-counter drugs market over the forecast period. Increasing healthcare expenditure and boosting economies of countries like China, India, Japan, and others due to continually growing population and rising disposable income in these countries are expected to create lucrative opportunities for the players in the Asia Pacific OTC drugs market during the forecast period. An increasing number of pharmaceutical companies, drug stores, supermarkets, retail outlets, hospital pharmacies, and e-commerce offers several opportunities to grow the over the counter drugs market in the Asia Pacific.
This research report on the Asia Pacific OTC Drugs Market has been segmented and sub-segmented into the following categories:
By Product Type:
By Formulation Type:
By Distribution Channels:
By Country:
The Japanese over the drugs market is forecasted to saturate soon due to economic stagnation. The increasing adoption of western lifestyles and growing prosperities leads to an increase in market size and OTC demand.
Some of the notable companies leading in the APAC over the Counter Drugs Market profiled in the report are GlaxoSmithKline, Johnson and Johnson, Novartis, Bayer, Pfizer, Sanofi, and Takeda.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Analgesics
5.1.2 Cough, Cold and Flu Products
5.1.3 Vitamins and Minerals
5.1.4 Dermatological Products
5.1.5 Gastrointestinal Products
5.1.6 Ophthalmic Products
5.1.7 Sleep Aid Products
5.1.8 Weight Loss/Diet Products
5.1.9 Others
5.2 By Formulation Type
5.2.1 Tablets
5.2.2 Liquids
5.2.3 Ointments
5.2.4 Sprays
5.3 Distribution Channels
5.3.1 Pharmacies
5.3.2 Supermarkets/Hypermarkets
5.3.3 Convenience stores
5.3.4 Others (Online Drug Stores)
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 GlaxoSmithKline
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Johnson and Johnson
8.3 Novartis
8.4 Bayer
8.5 Pfizer
8.6 Boehringer Ingelheim
8.7 Sanofi
8.8 Takeda
8.9 PGT Healthcare
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
